checkAd
    Startseite > Aktien > Apellis Pharmaceuticals > Nachrichten
    Apellis Pharmaceuticals Aktie
    48,08
     
    USD
    -3,58 %
    -1,79 USD
    Letzter Kurs 16:13:19 Nasdaq
    47,93
     
    USD
    200 STK
    Geldkurs 16:14:20
    48,08
     
    USD
    400 STK
    Briefkurs 16:14:20
    ISIN: US03753U1060 · WKN: A2JAAW · SYM: APLS · USA

    Neueste Nachrichten

    Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
    26.04.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
    23.04.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    04.04.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
    01.04.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
    11.03.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    06.03.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
    27.02.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
    26.02.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
    20.02.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    06.02.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
    26.01.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
    08.01.24 · globenewswire · Apellis Pharmaceuticals